{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:12:31Z","timestamp":1788793951747,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K23AG064029"],"award-info":[{"award-number":["K23AG064029"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG089380"],"award-info":[{"award-number":["R01AG089380"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14087-3","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:56:23Z","timestamp":1788749783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review"],"prefix":"10.1007","volume":"273","author":[{"given":"Anas","family":"Elgenidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Shir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav D.","family":"Piura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard L.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Duara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lachner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-5538","authenticated-orcid":false,"given":"Gregory S.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"14087_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214439","volume":"106","author":"N Satyadev","year":"2026","unstructured":"Satyadev N, Piura YD, Tipton PW, Dunham SR, Morris JC, Geschwind MD et al (2026) Standardizing \u201crapid\u201d: applying the Clinical Dementia Rating to define rapidly progressive dementia. Neurology 106:e214439. https:\/\/doi.org\/10.1212\/wnl.0000000000214439","journal-title":"Neurology"},{"key":"14087_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1212\/con.0000000000001089","volume":"28","author":"GS Day","year":"2022","unstructured":"Day GS (2022) Rapidly progressive dementia. Continuum (Minneap Minn) 28:901\u2013936. https:\/\/doi.org\/10.1212\/con.0000000000001089","journal-title":"Continuum (Minneap Minn)"},{"key":"14087_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ana.27297","volume":"98","author":"YD Piura","year":"2025","unstructured":"Piura YD, Satyadev N, Corriveau-Lecavalier N, Kuchenbecker LA, Haydu LE, Geschwind MD et al (2025) Decoding the clinical features that associate with progression, causes, and outcomes in patients with suspected rapidly progressive dementia. Ann Neurol 98:764\u2013776. https:\/\/doi.org\/10.1002\/ana.27297","journal-title":"Ann Neurol"},{"key":"14087_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214933","volume":"106","author":"RW van Steenhoven","year":"2026","unstructured":"van Steenhoven RW, Bastiaansen AEM, Kerstens J, Crijnen YS, Brand T, Brenner J et al (2026) Autoimmune encephalitis as treatment-responsive cause of rapidly progressive dementia: a multicenter prospective cohort study. Neurology 106:e214933. https:\/\/doi.org\/10.1212\/wnl.0000000000214933","journal-title":"Neurology"},{"key":"14087_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70316","volume":"21","author":"YD Piura","year":"2025","unstructured":"Piura YD, Figdore DJ, Lachner C, Bornhorst J, Algeciras-Schimnich A, Graff-Radford NR et al (2025) Diagnostic performance of plasma p-tau217 and A\u03b242\/40 biomarkers in the outpatient memory clinic. Alzheimers Dement 21:e70316. https:\/\/doi.org\/10.1002\/alz.70316","journal-title":"Alzheimers Dement"},{"key":"14087_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s1474-4422(20)30477-4","volume":"20","author":"P Hermann","year":"2021","unstructured":"Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD et al (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20:235\u2013246. https:\/\/doi.org\/10.1016\/s1474-4422(20)30477-4","journal-title":"Lancet Neurol"},{"key":"14087_CR7","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1212\/WNL.0000000000005860","volume":"91","author":"P Hermann","year":"2018","unstructured":"Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S et al (2018) Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology 91:e331\u2013e338. https:\/\/doi.org\/10.1212\/WNL.0000000000005860","journal-title":"Neurology"},{"key":"14087_CR8","doi-asserted-by":"publisher","first-page":"e1017","DOI":"10.1212\/wnl.0000000000010086","volume":"95","author":"DD Rhoads","year":"2020","unstructured":"Rhoads DD, Wrona A, Foutz A, Blevins J, Glisic K, Person M et al (2020) Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology 95:e1017\u2013e1026. https:\/\/doi.org\/10.1212\/wnl.0000000000010086","journal-title":"Neurology"},{"key":"14087_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25098","volume":"5","author":"D Shir","year":"2022","unstructured":"Shir D, Lazar EB, Graff-Radford J, Aksamit AJ, Cutsforth-Gregory JK, Jones DT et al (2022) Analysis of clinical features, diagnostic tests, and biomarkers in patients with suspected Creutzfeldt-Jakob disease, 2014\u20132021. JAMA Netw Open 5:e2225098. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25098","journal-title":"JAMA Netw Open"},{"key":"14087_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 30:1085\u20131095. https:\/\/doi.org\/10.1038\/s41591-024-02869-z","journal-title":"Nat Med"},{"key":"14087_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ana.26822","volume":"95","author":"LA Kuchenbecker","year":"2024","unstructured":"Kuchenbecker LA, Tipton PW, Martens Y, Brier MR, Satyadev N, Dunham SR et al (2024) Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia. Ann Neurol 95:299\u2013313. https:\/\/doi.org\/10.1002\/ana.26822","journal-title":"Ann Neurol"},{"key":"14087_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/s1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC et al (2021) New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol 20:222\u2013234. https:\/\/doi.org\/10.1016\/s1474-4422(20)30440-3","journal-title":"Lancet Neurol"},{"key":"14087_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-021-02350-y","volume":"142","author":"S Baiardi","year":"2021","unstructured":"Baiardi S, Rossi M, Mammana A, Appleby BS, Barria MA, Cal\u00ec I et al (2021) Phenotypic diversity of genetic Creutzfeldt-Jakob disease: a histo-molecular-based classification. Acta Neuropathol 142:707\u2013728. https:\/\/doi.org\/10.1007\/s00401-021-02350-y","journal-title":"Acta Neuropathol"},{"key":"14087_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0706-6","volume":"7","author":"M Rossi","year":"2019","unstructured":"Rossi M, Kai H, Baiardi S, Bartoletti-Stella A, Carl\u00e0 B, Zenesini C et al (2019) The characterization of AD\/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded A\u03b2 and prion proteins. Acta Neuropathol Commun 7:53. https:\/\/doi.org\/10.1186\/s40478-019-0706-6","journal-title":"Acta Neuropathol Commun"},{"key":"14087_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"14087_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"14087_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214076","volume":"105","author":"R Zayat","year":"2025","unstructured":"Zayat R, Piura YD, Appleby BS, Robinson MT, Day GS (2025) Palliative care resource utilization in patients with prion disease. Neurology 105:e214076. https:\/\/doi.org\/10.1212\/wnl.0000000000214076","journal-title":"Neurology"},{"key":"14087_CR18","unstructured":"ClinicalTrials.gov (2026) An Open-label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered PrP-siRNA in Adult Patients Diagnosed With Symptomatic Prion Disease (NCT07444580). https:\/\/clinicaltrials.gov\/study\/NCT07444580. Accessed August 12, 2026"},{"key":"14087_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ana.26812","volume":"95","author":"N Satyadev","year":"2024","unstructured":"Satyadev N, Tipton PW, Martens Y, Dunham SR, Geschwind MD, Morris JC et al (2024) Improving early recognition of treatment-responsive causes of rapidly progressive dementia: the STAM(3) P score. Ann Neurol 95:237\u2013248. https:\/\/doi.org\/10.1002\/ana.26812","journal-title":"Ann Neurol"},{"key":"14087_CR20","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a","journal-title":"Neurology"},{"key":"14087_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"14087_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.46319","volume":"5","author":"N Watson","year":"2022","unstructured":"Watson N, Hermann P, Ladogana A, Denouel A, Baiardi S, Colaizzo E et al (2022) Validation of revised international Creutzfeldt-Jakob disease surveillance network diagnostic criteria for sporadic Creutzfeldt-Jakob disease. JAMA Netw Open 5:e2146319. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.46319","journal-title":"JAMA Netw Open"},{"key":"14087_CR23","unstructured":"Centers for Disease Control and Prevention (2026) Clinical Overview of Creutzfeldt-Jakob Disease (CJD). https:\/\/www.cdc.gov\/creutzfeldt-jakob\/hcp\/clinical-overview\/index.html. Accessed June 18, 2026"},{"key":"14087_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1750-3639.1995.tb00625.x","volume":"5","author":"H Budka","year":"1995","unstructured":"Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F et al (1995) Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5:459\u2013466. https:\/\/doi.org\/10.1111\/j.1750-3639.1995.tb00625.x","journal-title":"Brain Pathol"},{"key":"14087_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s1474-4422(25)00451-x","volume":"25","author":"S Mead","year":"2026","unstructured":"Mead S, Hermann P, Mok TH, Parchi P, Zerr I (2026) Genetic causes and modifiers of prion diseases. Lancet Neurol 25:181\u2013194. https:\/\/doi.org\/10.1016\/s1474-4422(25)00451-x","journal-title":"Lancet Neurol"},{"key":"14087_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103910","volume":"95","author":"N Rabaneda-Lombarte","year":"2026","unstructured":"Rabaneda-Lombarte N, Ferrari-Souza JP, Celedon J, Zimmer ER, Dickerson BC, Arnold SE et al (2026) Real-world comparison of brain [(18)F]FDG-PET imaging with CSF Alzheimer\u2019s disease biomarkers in a tertiary memory clinic setting. EClinicalMedicine 95:103910. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103910","journal-title":"EClinicalMedicine"},{"key":"14087_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1212\/WNL.0b013e318263565f","volume":"79","author":"C Hamlin","year":"2012","unstructured":"Hamlin C, Puoti G, Berri S, Sting E, Harris C, Cohen M et al (2012) A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 79:547\u2013552. https:\/\/doi.org\/10.1212\/WNL.0b013e318263565f","journal-title":"Neurology"},{"key":"14087_CR28","unstructured":"Center NPDPS CSF Testing for Prion Markers. https:\/\/case.edu\/medicine\/pathology\/divisions\/national-prion-disease-pathology-surveillance-center\/clinical\/csf-testing-prion-markers. Accessed July 8, 2026"},{"key":"14087_CR29","unstructured":"Mayo Clinic Laboratories CJDE: Creutzfeldt-Jakob disease evaluation, spinal fluid. https:\/\/www.mayocliniclabs.com\/test-catalog\/overview\/620374#clinical-and-interpretive. Accessed July 23, 2026"},{"key":"14087_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","volume":"71","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Ros\u00e9n C, Asztely F, Mattsson N, Blennow K, Zetterberg H (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 71:476\u2013483. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6455","journal-title":"JAMA Neurol"},{"key":"14087_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:Ed000142. https:\/\/doi.org\/10.1002\/14651858.Ed000142","journal-title":"Cochrane Database Syst Rev"},{"key":"14087_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"14087_CR33","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al (2020) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds) JBI Manual for Evidence Synthesis. JBI, City","DOI":"10.46658\/JBIRM-17-06"},{"key":"14087_CR34","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1007\/s00415-022-11045-7","volume":"269","author":"N Corriveau-Lecavalier","year":"2022","unstructured":"Corriveau-Lecavalier N, Li W, Ramanan VK, Drubach DA, Day GS, Jones DT (2022) Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome. J Neurol 269:4222\u20134228. https:\/\/doi.org\/10.1007\/s00415-022-11045-7","journal-title":"J Neurol"},{"key":"14087_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/2013.jamaneurol.139","volume":"70","author":"DY Johnson","year":"2013","unstructured":"Johnson DY, Dunkelberger DL, Henry M, Haman A, Greicius MD, Wong K et al (2013) Sporadic Jakob-Creutzfeldt disease presenting as primary progressive aphasia. JAMA Neurol 70:254\u2013257. https:\/\/doi.org\/10.1001\/2013.jamaneurol.139","journal-title":"JAMA Neurol"},{"key":"14087_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12883-018-1055-y","volume":"18","author":"K Miyake","year":"2018","unstructured":"Miyake K, Hara T, Oshima E, Kawada K, Ishizu H, Yamauchi Y et al (2018) Creutzfeldt-Jakob disease with Alzheimer pathology, presenting with status epilepticus following repeated partial seizures: a case report and literature review. BMC Neurol 18:54. https:\/\/doi.org\/10.1186\/s12883-018-1055-y","journal-title":"BMC Neurol"},{"key":"14087_CR37","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1097\/RLU.0000000000001602","volume":"42","author":"N Miyazawa","year":"2017","unstructured":"Miyazawa N (2017) Creutzfeldt-Jakob disease mimicking Alzheimer disease and dementia with Lewy bodies-findings of FDG PET with 3-dimensional stereotactic surface projection. Clin Nucl Med 42:e247\u2013e248. https:\/\/doi.org\/10.1097\/RLU.0000000000001602","journal-title":"Clin Nucl Med"},{"key":"14087_CR38","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/ADR-230173","volume":"8","author":"AG Nanni","year":"2024","unstructured":"Nanni AG, Urso D, Caccamo M, Gnoni V, Giugno A, Zecca C et al (2024) An atypical case of Creutzfeldt-Jakob syndrome presenting with cacosmia and amyloid positivity. J Alzheimers Dis Rep 8:1105\u20131110. https:\/\/doi.org\/10.3233\/ADR-230173","journal-title":"J Alzheimers Dis Rep"},{"key":"14087_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/19336896.2016.1175698","volume":"10","author":"B Trikamji","year":"2016","unstructured":"Trikamji B, Hamlin C, Baldwin KJ (2016) A rare case of rapidly progressive dementia with elevated RT-QuIC and negative 14-3-3 and tau proteins. Prion 10:262\u2013264. https:\/\/doi.org\/10.1080\/19336896.2016.1175698","journal-title":"Prion"},{"key":"14087_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1176\/appi.neuropsych.20230205","volume":"37","author":"MK Wiggins","year":"2025","unstructured":"Wiggins MK, Pharr EP, Wood JL, Craft S, Harrison WT, Bateman JR (2025) Dementia with Lewy bodies phenocopy in a case of RT-QuIC\u2013negative Creutzfeldt-Jakob disease: implications of functional anatomy. J Neuropsychiatry Clin Neurosci 37:93\u201396. https:\/\/doi.org\/10.1176\/appi.neuropsych.20230205","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"14087_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fnbeh.2020.00055","volume":"14","author":"E Prodi","year":"2020","unstructured":"Prodi E, Rossi S, Bertaina I, Pravata E, Sacco L (2020) Report of a case of Creutzfeldt-Jakob disease with an unusual clinical presentation. Front Behav Neurosci 14:55. https:\/\/doi.org\/10.3389\/fnbeh.2020.00055","journal-title":"Front Behav Neurosci"},{"key":"14087_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s1474-4422(05)70192-7","volume":"4","author":"RT Johnson","year":"2005","unstructured":"Johnson RT (2005) Prion diseases. Lancet Neurol 4:635\u2013642. https:\/\/doi.org\/10.1016\/s1474-4422(05)70192-7","journal-title":"Lancet Neurol"},{"key":"14087_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhin.2022.08.014","volume":"132","author":"KA Schwenke","year":"2023","unstructured":"Schwenke KA, Wagenf\u00fchr K, Thanheiser M, Beekes M (2023) Kinetics of the reduction of Creutzfeldt-Jakob disease prion seeding activity by steam sterilization support the use of validated 134\u00b0C programmes. J Hosp Infect 132:125\u2013132. https:\/\/doi.org\/10.1016\/j.jhin.2022.08.014","journal-title":"J Hosp Infect"},{"key":"14087_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1556","volume":"5","author":"AL Porter","year":"2022","unstructured":"Porter AL, Prusinski CC, Lazar E, Yuh C, Bucelli RC, Appleby BS et al (2022) Prevalence of surgical procedures at symptomatic onset of prion disease. JAMA Netw Open 5:e221556. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1556","journal-title":"JAMA Netw Open"},{"key":"14087_CR45","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.gim.2022.06.003","volume":"24","author":"JS Goldman","year":"2022","unstructured":"Goldman JS, Vallabh SM (2022) Genetic counseling for prion disease: updates and best practices. Genet Med 24:1993\u20132003. https:\/\/doi.org\/10.1016\/j.gim.2022.06.003","journal-title":"Genet Med"},{"key":"14087_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/wad.0000000000000276","volume":"32","author":"GS Day","year":"2018","unstructured":"Day GS, Musiek ES, Morris JC (2018) Rapidly progressive dementia in the outpatient clinic: more than prions. Alzheimer Dis Assoc Disord 32:291\u2013297. https:\/\/doi.org\/10.1097\/wad.0000000000000276","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"14087_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/WAD.0b013e31819e099b","volume":"23","author":"SG Papageorgiou","year":"2009","unstructured":"Papageorgiou SG, Kontaxis T, Bonakis A, Karahalios G, Kalfakis N, Vassilopoulos D (2009) Rapidly progressive dementia: causes found in a Greek tertiary referral center in Athens. Alzheimer Dis Assoc Disord 23:337\u2013346. https:\/\/doi.org\/10.1097\/WAD.0b013e31819e099b","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"14087_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71345","volume":"22","author":"A Association","year":"2026","unstructured":"Association A (2026) 2026 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 22:e71345. https:\/\/doi.org\/10.1002\/alz.71345","journal-title":"Alzheimers Dement"},{"key":"14087_CR49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000439251","volume":"15","author":"O Grau-Rivera","year":"2015","unstructured":"Grau-Rivera O, Gelpi E, Nos C, Gaig C, Ferrer I, Saiz A et al (2015) Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis 15:350\u2013360. https:\/\/doi.org\/10.1159\/000439251","journal-title":"Neurodegener Dis"},{"key":"14087_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s004010050870","volume":"96","author":"JA Hainfellner","year":"1998","unstructured":"Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96:116\u2013122. https:\/\/doi.org\/10.1007\/s004010050870","journal-title":"Acta Neuropathol"},{"key":"14087_CR51","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/archneurol.2009.224","volume":"66","author":"N Ghoshal","year":"2009","unstructured":"Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P et al (2009) Codistribution of amyloid \u03b2 plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K\u2013129M haplotype. Arch Neurol 66:1240\u20131246. https:\/\/doi.org\/10.1001\/archneurol.2009.224","journal-title":"Arch Neurol"},{"key":"14087_CR52","doi-asserted-by":"publisher","first-page":"e896","DOI":"10.1212\/WNL.0000000000005064","volume":"90","author":"GS Day","year":"2018","unstructured":"Day GS, Gordon BA, Perrin RJ, Cairns NJ, Beaumont H, Schwetye K et al (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology 90:e896\u2013e906. https:\/\/doi.org\/10.1212\/WNL.0000000000005064","journal-title":"Neurology"},{"key":"14087_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214712","volume":"107","author":"T Coysh","year":"2026","unstructured":"Coysh T, Laban R, Veleva E, Heslegrave AJ, Darwent L, Holm-Mercer L et al (2026) Performance of Alzheimer disease plasma biomarkers in patients with prion diseases. Neurology 107:e214712. https:\/\/doi.org\/10.1212\/WNL.0000000000214712","journal-title":"Neurology"},{"key":"14087_CR54","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1002\/alz.13907","volume":"20","author":"A Emer\u0161i\u010d","year":"2024","unstructured":"Emer\u0161i\u010d A, Ashton NJ, Vrillon A, Lantero-Rodriguez J, Mlakar J, Gregori\u010d Kramberger M et al (2024) Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies. Alzheimers Dement 20:5324\u20135337. https:\/\/doi.org\/10.1002\/alz.13907","journal-title":"Alzheimers Dement"},{"key":"14087_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/v14020276","volume":"14","author":"P Hermann","year":"2022","unstructured":"Hermann P, Haller P, Goebel S, Bunck T, Schmidt C, Wiltfang J et al (2022) Total and phosphorylated cerebrospinal fluid tau in the differential diagnosis of sporadic Creutzfeldt-Jakob disease and rapidly progressive Alzheimer\u2019s disease. Viruses 14:276. https:\/\/doi.org\/10.3390\/v14020276","journal-title":"Viruses"},{"key":"14087_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.clinph.2005.12.007","volume":"117","author":"HG Wieser","year":"2006","unstructured":"Wieser HG, Schindler K, Zumsteg D (2006) EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol 117:935\u2013951. https:\/\/doi.org\/10.1016\/j.clinph.2005.12.007","journal-title":"Clin Neurophysiol"},{"key":"14087_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-153","volume":"12","author":"C Carswell","year":"2012","unstructured":"Carswell C, Thompson A, Lukic A, Stevens J, Rudge P, Mead S et al (2012) MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease. BMC Neurol 12:153. https:\/\/doi.org\/10.1186\/1471-2377-12-153","journal-title":"BMC Neurol"},{"key":"14087_CR58","first-page":"A213","volume":"74","author":"M Geschwind","year":"2010","unstructured":"Geschwind M, Cattaruzza T, Vitali P, DeArmond S, Wong K (2010) Brain MRI in sporadic Jakob-Creutzfeldt disease is often misread. Neurology 74:A213","journal-title":"Neurology"},{"key":"14087_CR59","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.wnl.0000184674.32924.c9","volume":"65","author":"B Meissner","year":"2005","unstructured":"Meissner B, Westner IM, Kallenberg K, Krasnianski A, Bartl M, Varges D et al (2005) Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65:1544\u20131550. https:\/\/doi.org\/10.1212\/01.wnl.0000184674.32924.c9","journal-title":"Neurology"},{"key":"14087_CR60","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archneur.63.6.876","volume":"63","author":"A Krasnianski","year":"2006","unstructured":"Krasnianski A, Meissner B, Schulz-Schaeffer W, Kallenberg K, Bartl M, Heinemann U et al (2006) Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol 63:876\u2013880. https:\/\/doi.org\/10.1001\/archneur.63.6.876","journal-title":"Arch Neurol"},{"key":"14087_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01249-y","volume":"15","author":"JM Herden","year":"2023","unstructured":"Herden JM, Hermann P, Schmidt I, Dittmar K, Canaslan S, Weglage L et al (2023) Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer\u2019s disease. Alzheimers Res Ther 15:106. https:\/\/doi.org\/10.1186\/s13195-023-01249-y","journal-title":"Alzheimers Res Ther"},{"key":"14087_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","volume":"10","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther 10:3. https:\/\/doi.org\/10.1186\/s13195-017-0331-1","journal-title":"Alzheimers Res Ther"},{"key":"14087_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00769-19","volume":"57","author":"A Connor","year":"2019","unstructured":"Connor A, Wang H, Appleby BS, Rhoads DD (2019) Clinical laboratory tests used to aid in diagnosis of human prion disease. J Clin Microbiol 57:e00769. https:\/\/doi.org\/10.1128\/jcm.00769-19","journal-title":"J Clin Microbiol"},{"key":"14087_CR64","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra2119323","volume":"386","author":"I Zerr","year":"2022","unstructured":"Zerr I (2022) Laboratory diagnosis of Creutzfeldt-Jakob disease. N Engl J Med 386:1345\u20131350. https:\/\/doi.org\/10.1056\/NEJMra2119323","journal-title":"N Engl J Med"},{"key":"14087_CR65","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1038\/s41380-021-01045-w","volume":"26","author":"AGB Thompson","year":"2021","unstructured":"Thompson AGB, Anastasiadis P, Druyeh R, Whitworth I, Nayak A, Nihat A et al (2021) Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry 26:5955\u20135966. https:\/\/doi.org\/10.1038\/s41380-021-01045-w","journal-title":"Mol Psychiatry"},{"key":"14087_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep 6:38737. https:\/\/doi.org\/10.1038\/srep38737","journal-title":"Sci Rep"},{"key":"14087_CR67","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/jnen\/nlac113","volume":"82","author":"I Kortazar-Zubizarreta","year":"2023","unstructured":"Kortazar-Zubizarreta I, Era\u00f1a H, Pereda A, Charco JM, Manero-Azua A, Ruiz-Onandi R et al (2023) Analysis of a large case series of fatal familial insomnia to determine tests with the highest diagnostic value. J Neuropathol Exp Neurol 82:169\u2013179. https:\/\/doi.org\/10.1093\/jnen\/nlac113","journal-title":"J Neuropathol Exp Neurol"},{"key":"14087_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70425","author":"C-J Li","year":"2026","unstructured":"Li C-J, Liang D-L, Gao L-P, Zhang W-W, Zhou W, Ruhan A et al (2026) Comprehensive characterization of 98 Chinese cases of genetic Creutzfeldt-Jakob disease with T188K mutation. Ann Clin Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.70425","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14087-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14087-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:03:56Z","timestamp":1788793436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14087-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14087"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14087-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sokol has received consulting or advisory fees from Remo Health, Eli Lilly, NewAmsterdam Pharma, Jefferies, GE HealthCare, and AKH Inc.\/Catalyst Medical Education; the latter activity was supported by an independent educational grant from Axsome Therapeutics. He has received research support from Huntington\u2019s Disease Society of America and institutional research support from Scripps Clinic\/The Scripps Research Institute. He is employed by the Wien Center for Alzheimer\u2019s Disease and Memory Disorders at Mount Sinai Medical Center in Miami Beach, Florida. The institution receives research funding from the NIH, the Florida Department of Health, nonprofit organizations, and industry sponsors. These relationships were unrelated to the design, conduct, interpretation, or reporting of the present work. Prior consulting, honoraria, research support, and employment relationships do not imply endorsement by, or reflect the official views or values of, the organizations involved. Dr. Day reports no competing interests directly relevant to this work. His research is supported by NIH (R01AG089380, U01AG057195, U01NS120901, U19AG032438, P30AG062677). He serves as a Topic Editor (Dementia) for DynaMed (EBSCO). He is a co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from NIH\/NINDS (U01NS120901) and Amgen Pharmaceuticals. He has developed educational materials for Continuing Education Inc, and MJH Life Sciences. He owns stock in ANI Pharmaceuticals. Dr. Day\u2019s institution has received in-kind contributions for radiotracer precursors for tau-PET neuroimaging in studies of memory and aging (via Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental procedure was approved by the ethics committee of Mayo Clinic and complied with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants or legal guardians included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"565"}}